Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Working Capital Changes (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Other Working Capital Changes for 3 consecutive years, with -$38000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 107.05% to -$38000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$369000.0 through Dec 2025, down 107.6% year-over-year, with the annual reading at -$369000.0 for FY2025, 107.6% down from the prior year.
  • Other Working Capital Changes hit -$38000.0 in Q4 2025 for Compass Therapeutics, down from -$37000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.0 million in Q3 2024 to a low of -$5.9 million in Q4 2023.
  • Historically, Other Working Capital Changes has averaged -$189500.0 across 3 years, with a median of -$37500.0 in 2025.
  • Biggest five-year swings in Other Working Capital Changes: surged 544.55% in 2024 and later tumbled 127.03% in 2025.
  • Year by year, Other Working Capital Changes stood at -$5.9 million in 2023, then skyrocketed by 109.18% to $539000.0 in 2024, then crashed by 107.05% to -$38000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for CMPX at -$38000.0 in Q4 2025, -$37000.0 in Q3 2025, and -$41000.0 in Q2 2025.